{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:36:54Z","timestamp":1792442214850,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cpet.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:26:12Z","timestamp":1761654372000},"page":"117-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mathematical and Computational Nuclear Oncology"],"prefix":"10.1016","volume":"21","author":[{"given":"Marc","family":"Ryhiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangmeihui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Saboury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Glatting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Rahmim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.cpet.2025.09.005_bib1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"10276","key":"10.1016\/j.cpet.2025.09.005_bib2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.cpet.2025.09.005_bib3","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.cpet.2025.09.005_bib4","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2967\/jnumed.124.267951","article-title":"177 Lu-PSMA (R)Evolution in cancer care: is it really happening?","volume":"65","author":"Poschenrieder","year":"2024","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2025.09.005_bib5","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1002\/mp.13820","article-title":"Personalized dosimetry is a must for appropriate molecular radiotherapy","volume":"46","author":"Stabin","year":"2019","journal-title":"Med Phys"},{"issue":"14","key":"10.1016\/j.cpet.2025.09.005_bib6","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.3390\/cancers13143607","article-title":"Target heterogeneity in oncology: the best predictor for differential response to radioligand therapy in neuroendocrine tumors and prostate cancer","volume":"13","author":"Puranik","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40644-022-00505-y","article-title":"Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer","volume":"22","author":"Beauregard","year":"2022","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.cpet.2025.09.005_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1062592","article-title":"Theranostic digital twins for personalized radiopharmaceutical therapies: reimagining theranostics via computational nuclear oncology","volume":"12","author":"Rahmim","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpet.2025.09.005_bib9","doi-asserted-by":"crossref","first-page":"25732","DOI":"10.1109\/ACCESS.2022.3156062","article-title":"Digital twin perspective of fourth industrial and healthcare revolution","volume":"10","author":"Khan","year":"2022","journal-title":"IEEE Access"},{"issue":"04","key":"10.1016\/j.cpet.2025.09.005_bib10","first-page":"1","article-title":"Virtual clinical trials in medical imaging: a review","volume":"7","author":"Abadi","year":"2020","journal-title":"J Med Imaging"},{"issue":"5","key":"10.1016\/j.cpet.2025.09.005_bib11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00259-015-3248-6","article-title":"The role of patient-based treatment planning in peptide receptor radionuclide therapy","volume":"43","author":"Hardiansyah","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2967\/jnumed.118.210377","article-title":"Modeling and predicting tumor response in radioligand therapy","volume":"60","author":"Kletting","year":"2019","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2025.09.005_bib13","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.7150\/thno.93249","article-title":"Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177 Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside","volume":"14","author":"Arbuznikova","year":"2024","journal-title":"Theranostics"},{"issue":"17","key":"10.1016\/j.cpet.2025.09.005_bib14","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/1078-0432.CCR-21-4332","article-title":"Combining targeted radionuclide therapy and immune checkpoint inhibition for cancer treatment","volume":"28","author":"Kleinendorst","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67199-9","article-title":"Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP","volume":"10","author":"Cullinane","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpet.2025.09.005_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2025.112166","article-title":"Digital twins in radiology: a systematic review of applications, challenges, and future perspectives","volume":"189","author":"Faiella","year":"2025","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cpet.2025.09.005_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF02982830","article-title":"The mechanism of the induction by radiation of chromosome aberration in tradescantia","volume":"44","author":"Lea","year":"1942","journal-title":"J Genet"},{"issue":"9","key":"10.1016\/j.cpet.2025.09.005_bib18","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.7150\/thno.93973","article-title":"Theranostic digital twins: concept, framework and roadmap towards personalized radiopharmaceutical therapies","volume":"14","author":"Abdollahi","year":"2024","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.cpet.2025.09.005_bib19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/rs14061335","article-title":"Digital twin technology challenges and applications: a comprehensive review","volume":"14","author":"Bot\u00edn-Sanabria","year":"2022","journal-title":"Remote Sens"},{"issue":"4","key":"10.1016\/j.cpet.2025.09.005_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2967\/jnumed.124.267927","article-title":"Computational nuclear oncology toward precision radiopharmaceutical therapies: current tools, techniques, and uncharted territories","volume":"66","author":"Yusufaly","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2025.09.005_bib21","doi-asserted-by":"crossref","DOI":"10.18502\/fbt.v10i1.11505","article-title":"Digital twins for personalized healthcare: application to radiopharmaceutical therapies","author":"Abdollahi","year":"2022","journal-title":"Frontiers in Biomedical Technologies"},{"issue":"5","key":"10.1016\/j.cpet.2025.09.005_bib22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2967\/jnumed.124.268186","article-title":"Computational nuclear oncology toward precision radiopharmaceutical therapies: ethical, regulatory, and socioeconomic dimensions of Theranostic digital twins","volume":"66","author":"Strigari","year":"2025","journal-title":"J Nucl Med"},{"issue":"Supplement 3","key":"10.1016\/j.cpet.2025.09.005_bib23","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.2967\/jnumed.121.262751","article-title":"Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns","volume":"62","author":"Wahl","year":"2021","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2025.09.005_bib24","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/2767-9764.CRC-24-0306","article-title":"Mathematical modeling unveils optimization strategies for targeted radionuclide therapy of blood cancers","volume":"4","author":"Kuznetsov","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"4","key":"10.1016\/j.cpet.2025.09.005_bib25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2025.09.005_bib26","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1002\/mp.13049","article-title":"Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk","volume":"45","author":"Jim\u00e9nez-Franco","year":"2018","journal-title":"Med Phys"},{"issue":"7","key":"10.1016\/j.cpet.2025.09.005_bib27","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.3390\/ijms24076856","article-title":"Computer-assisted design of peptide-based radiotracers","volume":"24","author":"Patamia","year":"2023","journal-title":"IJMS"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56603-8","article-title":"The effect of ligand amount, affinity and internalization on PSMA-Targeted imaging and therapy: a simulation study using a PBPK model","volume":"9","author":"Begum","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpet.2025.09.005_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.radphyschem.2024.111649","article-title":"Digital twins in dosimetry and radiotherapy, a survey and some applications","volume":"218","author":"Sumini","year":"2024","journal-title":"Radiat Phys Chem"},{"issue":"10","key":"10.1016\/j.cpet.2025.09.005_bib30","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3390\/cancers16101879","article-title":"Integrating imaging and circulating tumor DNA features for predicting patient outcomes","volume":"16","author":"Magbanua","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13073-024-01315-6","article-title":"Deep learning in cancer genomics and histopathology","volume":"16","author":"Unger","year":"2024","journal-title":"Genome Med"},{"issue":"22","key":"10.1016\/j.cpet.2025.09.005_bib32","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/cncr.28860","article-title":"PET\/CT imaging in cancer: current applications and future directions","volume":"120","author":"Farwell","year":"2014","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.cpet.2025.09.005_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00432-025-06184-z","article-title":"PSMA PET\/CT for prostate cancer diagnosis: current applications and future directions","volume":"151","author":"Shen","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2025.09.005_bib34","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1088\/0031-9155\/60\/6\/2547","article-title":"Exploring the quantitative relationship between metabolism and enzymatic phenotype by physiological modeling of glucose metabolism and lactate oxidation in solid tumors","volume":"60","author":"Wang","year":"2015","journal-title":"Phys Med Biol"},{"issue":"18","key":"10.1016\/j.cpet.2025.09.005_bib35","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.7150\/thno.19782","article-title":"Quantitative imaging for targeted radionuclide therapy dosimetry - technical review","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.cpet.2025.09.005_bib36","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.2147\/OTT.S140671","article-title":"Theranostics in nuclear medicine practice","volume":"10","author":"Yordanova","year":"2017","journal-title":"OTT"},{"issue":"10","key":"10.1016\/j.cpet.2025.09.005_bib37","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s12276-022-00863-4","article-title":"DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities","volume":"54","author":"Abuetabh","year":"2022","journal-title":"Exp Mol Med"},{"issue":"D1","key":"10.1016\/j.cpet.2025.09.005_bib38","doi-asserted-by":"crossref","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","article-title":"ClinVar: public archive of interpretations of clinically relevant variants","volume":"44","author":"Landrum","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cpet.2025.09.005_bib39","article-title":"Linking microdosimetric measurements to biological effectiveness: a review of theoretical aspects of MKM and other models","author":"Bellinzona","year":"2021","journal-title":"arXiv"},{"issue":"8","key":"10.1016\/j.cpet.2025.09.005_bib40","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2967\/jnumed.125.269470","article-title":"Establishing in vitro dosimetric models and dose\u2013effect relationships for177 Lu-DOTATATE in neuroendocrine tumors","volume":"66","author":"Tamborino","year":"2025","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2025.09.005_bib41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/17425255.2015.1037276","article-title":"Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps","volume":"11","author":"Block","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.cpet.2025.09.005_bib42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2967\/jnumed.109.067546","article-title":"Radioimmunotherapy with Anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model","volume":"51","author":"Kletting","year":"2010","journal-title":"J Nucl Med"},{"issue":"14","key":"10.1016\/j.cpet.2025.09.005_bib43","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.3390\/cancers13143429","article-title":"Is hypoxia a factor influencing PSMA-directed radioligand therapy?\u2014an in silico study on the role of chronic hypoxia in prostate cancer","volume":"13","author":"Birindelli","year":"2021","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.cpet.2025.09.005_bib44","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.7150\/thno.99516","article-title":"Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics","volume":"14","author":"Hong","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.cpet.2025.09.005_bib45","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07144-y","article-title":"A mathematical model for the investigation of combined treatment of radiopharmaceutical therapy and PARP inhibitors","author":"Ryhiner","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib46","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"Van Leeuwen","year":"2018","journal-title":"Radiat Oncol"},{"issue":"7035","key":"10.1016\/j.cpet.2025.09.005_bib47","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cpet.2025.09.005_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2024.1355912","article-title":"Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium","volume":"4","author":"Ramonaheng","year":"2024","journal-title":"Front Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2025.09.005_bib49","first-page":"1665","article-title":"A pipeline for automated voxel dosimetry: application in patients with multi-SPECT\/CT imaging following177 Lu peptide receptor radionuclide therapy","volume":"63","author":"Dewaraja","year":"2022","journal-title":"J Nucl Med"},{"issue":"1135","key":"10.1016\/j.cpet.2025.09.005_bib50","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20220056","article-title":"Milestones in dosimetry for nuclear medicine therapy","volume":"95","author":"Gear","year":"2022","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.cpet.2025.09.005_bib51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MNM.0b013e3282f3a515","article-title":"PET versus SPECT: strengths, limitations and challenges","volume":"29","author":"Rahmim","year":"2008","journal-title":"Nucl Med Commun"},{"issue":"7","key":"10.1016\/j.cpet.2025.09.005_bib52","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3390\/diagnostics13071210","article-title":"An overview of in vitro assays of 64Cu-68Ga-125I-and 99mTc-Labelled radiopharmaceuticals using radiometric counters in the era of radiotheranostics","volume":"13","author":"Benfante","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.cpet.2025.09.005_bib53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.nucmedbio.2019.05.003","article-title":"Modelling the internalisation process of prostate cancer cells for PSMA-Specific ligands","volume":"72-73","author":"Winter","year":"2019","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.cpet.2025.09.005_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2024.103299","article-title":"A PBPK model for PRRT with [177Lu]Lu-DOTA-TATE: comparison of model implementations in SAAM II and MATLAB\/simBiology","volume":"119","author":"Vasi\u0107","year":"2024","journal-title":"Phys Med"},{"issue":"2","key":"10.1016\/j.cpet.2025.09.005_bib55","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2967\/jnumed.108.054189","article-title":"Improving Anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model","volume":"50","author":"Kletting","year":"2009","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2025.09.005_bib56","first-page":"528","article-title":"Mathematical modeling of in vivo alpha particle generators and chelator stability","volume":"38","author":"Zaid","year":"2023","journal-title":"Cancer Biother Rad"},{"issue":"12","key":"10.1016\/j.cpet.2025.09.005_bib57","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/pharmaceutics13122132","article-title":"A physiologically based pharmacokinetic model for in vivo alpha particle generators targeting neuroendocrine tumors in mice","volume":"13","author":"Zaid","year":"2021","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.cpet.2025.09.005_bib58","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10928-018-9608-7","article-title":"MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues","volume":"45","author":"Lavezzi","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"10.1016\/j.cpet.2025.09.005_bib59","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1109\/TRPMS.2024.3381849","article-title":"PBPK-adapted deep learning for pretherapy prediction of voxelwise dosimetry: in-silico proof of concept","volume":"8","author":"Kassar","year":"2024","journal-title":"IEEE Trans Radiat Plasma Med Sci"},{"key":"10.1016\/j.cpet.2025.09.005_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.radphyschem.2025.112906","article-title":"Alpha-emitters dose point kernel in biological tissues for nuclear medicine applications","volume":"236","author":"Scarinci","year":"2025","journal-title":"Radiat Phys Chem"},{"issue":"2","key":"10.1016\/j.cpet.2025.09.005_bib61","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2967\/jnmt.123.265668","article-title":"The MIRD schema for radiopharmaceutical dosimetry: a review","volume":"52","author":"Zanzonico","year":"2024","journal-title":"J Nucl Med Technol"},{"issue":"3","key":"10.1016\/j.cpet.2025.09.005_bib62","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry\u2014standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2025.09.005_bib63","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1002\/mp.17256","article-title":"Review of chemical models and applications in Geant4-DNA: report from the ESA BioRad III project","volume":"51","author":"Tran","year":"2024","journal-title":"Med Phys"},{"issue":"19","key":"10.1016\/j.cpet.2025.09.005_bib64","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1088\/0031-9155\/49\/19\/007","article-title":"GATE: a simulation toolkit for PET and SPECT","volume":"49","author":"Jan","year":"2004","journal-title":"Phys Med Biol"},{"issue":"9","key":"10.1016\/j.cpet.2025.09.005_bib65","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2967\/jnumed.121.263253","article-title":"MIRD pamphlet no. 27: MIRDcell V3, a revised software tool for multicellular dosimetry and bioeffect modeling","volume":"63","author":"Katugampola","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2025.09.005_bib66","first-page":"17","article-title":"Introduction to monte carlo simulation","volume":"1204","author":"Harrison","year":"2010"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13014-018-1065-3","article-title":"Monte carlo simulations in radiotherapy dosimetry","volume":"13","author":"Andreo","year":"2018","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib68","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/pro6.1186","article-title":"Simulation of DNA damage using Geant4-DNA: an overview of the \u201cmolecularDNA\u201d example application","volume":"7","author":"Chatzipapas","year":"2023","journal-title":"Precision Radiation Oncology"},{"key":"10.1016\/j.cpet.2025.09.005_bib69","doi-asserted-by":"crossref","unstructured":"Lopez-Montes A, et al. Artificial intelligence for simplified patient-friendly dosimetry in radiopharmaceutical therapies. Pet Clin, 2026; Published online.","DOI":"10.1016\/j.cpet.2025.09.010"},{"issue":"20","key":"10.1016\/j.cpet.2025.09.005_bib70","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ad7cbe","article-title":"Dose-rate effects and tumor control probability in177 Lu-based targeted radionuclide therapy: a theoretical analysis","volume":"69","author":"Galler","year":"2024","journal-title":"Phys Med Biol"},{"issue":"5","key":"10.1016\/j.cpet.2025.09.005_bib72","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3892\/ijo.2013.1857","article-title":"Cell survival and radiosensitisation: modulation of the linear and quadratic parameters of the LQ model","volume":"42","author":"Franken","year":"2013","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2025.09.005_bib71","first-page":"303","article-title":"Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-Values for radionuclides uniformly distributed in different cell compartments","volume":"35","author":"Goddu","year":"1994","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib73","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/aaf26a","article-title":"The linear quadratic model: usage, interpretation and challenges","volume":"64","author":"McMahon","year":"2018","journal-title":"Phys Med Biol"},{"issue":"7","key":"10.1016\/j.cpet.2025.09.005_bib74","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1140\/epjp\/s13360-024-05318-5","article-title":"On the radiation quality characterization in radiation therapy: from linear energy transfer to experimental microdosimetry","volume":"139","author":"Missiaggia","year":"2024","journal-title":"Eur Phys J Plus"},{"issue":"21","key":"10.1016\/j.cpet.2025.09.005_bib75","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.3390\/ijms20215350","article-title":"The impact of dose rate on DNA double-strand break formation and repair in human lymphocytes exposed to fast neutron irradiation","volume":"20","author":"Nair","year":"2019","journal-title":"IJMS"},{"key":"10.1016\/j.cpet.2025.09.005_bib76","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.21.2.433","article-title":"Misrepair of radiation-induced DNA double-strand breaks and its relevance for tumorigenesis and cancer treatment (review)","author":"Rothkamm","year":"2002","journal-title":"Int J Oncol"},{"issue":"845","key":"10.1016\/j.cpet.2025.09.005_bib145","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1259\/bjr.71.845.9691890","article-title":"The clinical radiobiology of brachytherapy","volume":"71","author":"Dale","year":"1998","journal-title":"The British Journal of Radiology"},{"issue":"4","key":"10.1016\/j.cpet.2025.09.005_bib77","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.semradonc.2008.04.004","article-title":"The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction","volume":"18","author":"Brenner","year":"2008","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib78","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1667\/RR3394","article-title":"Evidence for complexity at the nanometer scale of radiation-induced DNA DSBs as a determinant of rejoining kinetics","volume":"164","author":"Pinto","year":"2005","journal-title":"Radiat Res"},{"issue":"690","key":"10.1016\/j.cpet.2025.09.005_bib79","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1259\/0007-1285-58-690-515","article-title":"The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy","volume":"58","author":"Dale","year":"1985","journal-title":"BJR"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib80","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.117.193706","article-title":"Dose mapping after endoradiotherapy with177 Lu-DOTATATE\/DOTATOC by a single measurement after 4 days","volume":"59","author":"H\u00e4nscheid","year":"2018","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib81","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2967\/jnumed.124.268457","article-title":"Mathematic modeling of tumor growth during [177 Lu]Lu-PSMA therapy: insights into treatment optimization","volume":"66","author":"Zaid","year":"2025","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2025.09.005_bib82","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00259-022-05821-w","article-title":"In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T","volume":"49","author":"Ruigrok","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.cpet.2025.09.005_bib83","first-page":"363","article-title":"Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy","volume":"19","author":"Dale","year":"2004","journal-title":"Cancer Biother Rad"},{"issue":"2","key":"10.1016\/j.cpet.2025.09.005_bib84","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/cancers11020205","article-title":"Mechanistic modelling of radiation responses","volume":"11","author":"McMahon","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.cpet.2025.09.005_bib85","doi-asserted-by":"crossref","unstructured":"Yusufaly T, et al. Multiscale computational radiobiology for precision radiopharmaceutical therapies. Pet Clin, 2026. Published online.","DOI":"10.1016\/j.cpet.2025.08.005"},{"key":"10.1016\/j.cpet.2025.09.005_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.689112","article-title":"A mechanistic DNA repair and survival model (medras): applications to intrinsic radiosensitivity, relative biological effectiveness and dose-rate","volume":"11","author":"McMahon","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/srep33290","article-title":"Mechanistic modelling of DNA repair and cellular survival following radiation-induced DNA damage","volume":"6","author":"McMahon","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10820-1","article-title":"A general mechanistic model enables predictions of the biological effectiveness of different qualities of radiation","volume":"7","author":"McMahon","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpet.2025.09.005_bib89","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07390-0","article-title":"Targeted alpha therapy: a comprehensive analysis of the biological effects from \u201clocal-regional-systemic\u201d dimensions","author":"Song","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"15","key":"10.1016\/j.cpet.2025.09.005_bib90","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.3390\/cancers13153751","article-title":"A spatial quantitative systems pharmacology platform spQSP-IO for simulations of tumor\u2013immune interactions and effects of checkpoint inhibitor immunotherapy","volume":"13","author":"Gong","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib91","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1871520615666150824153523","article-title":"The immune system in cancer prevention, development and therapy","volume":"16","author":"Candeias S","year":"2015","journal-title":"ACAMC"},{"issue":"2","key":"10.1016\/j.cpet.2025.09.005_bib92","doi-asserted-by":"crossref","first-page":"767","DOI":"10.7150\/thno.79806","article-title":"Radiopharmaceuticals heat anti-tumor immunity","volume":"13","author":"Sun","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.cpet.2025.09.005_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.667658","article-title":"Immunophenotyping reveals longitudinal changes in circulating immune cells during Radium-223 therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Creemers","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpet.2025.09.005_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.742215","article-title":"Hypoxia in solid tumors: how low oxygenation impacts the \u201cSix Rs\u201d of radiotherapy","volume":"12","author":"Rakotomalala","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.cpet.2025.09.005_bib95","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.2147\/IJN.S140462","article-title":"Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment","volume":"13","author":"Graham","year":"2018","journal-title":"IJN"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib96","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1748-717X-6-171","article-title":"Theoretical analysis of the dose dependence of the oxygen enhancement ratio and its relevance for clinical applications","volume":"6","author":"Wenzl","year":"2011","journal-title":"Radiat Oncol"},{"issue":"8","key":"10.1016\/j.cpet.2025.09.005_bib97","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1158\/0008-5472.CAN-20-1624","article-title":"Cytoplasmic localization of prostate-specific membrane antigen inhibitors may confer advantages for targeted cancer therapies","volume":"81","author":"Matthias","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib98","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40658-018-0217-8","article-title":"Comparison of radiobiological parameters for 90Y radionuclide therapy (RNT) and external beam radiotherapy (EBRT) in vitro","volume":"5","author":"Gholami","year":"2018","journal-title":"EJNMMI Phys"},{"issue":"11","key":"10.1016\/j.cpet.2025.09.005_bib99","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nrc2248","article-title":"The impact of a negligent G2\/M checkpoint on genomic instability and cancer induction","volume":"7","author":"L\u00f6brich","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.cpet.2025.09.005_bib100","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s10439-024-03650-6","article-title":"A comparative analysis of alpha and beta therapy in prostate cancer using a 3D image-based spatiotemporal model","volume":"53","author":"Piranfar","year":"2025","journal-title":"Ann Biomed Eng"},{"key":"10.1016\/j.cpet.2025.09.005_bib101","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2018.01.001","article-title":"Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials","volume":"123","author":"Marcu","year":"2018","journal-title":"Crit Rev Oncol-Hematol"},{"issue":"13","key":"10.1016\/j.cpet.2025.09.005_bib102","doi-asserted-by":"crossref","first-page":"L15","DOI":"10.1088\/0031-9155\/52\/13\/L01","article-title":"Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer","volume":"52","author":"Allen","year":"2007","journal-title":"Phys Med Biol"},{"issue":"11","key":"10.1016\/j.cpet.2025.09.005_bib103","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2967\/jnumed.120.248062","article-title":"Combination strategies to improve targeted radionuclide therapy","volume":"61","author":"Chan","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpet.2025.09.005_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"14","key":"10.1016\/j.cpet.2025.09.005_bib146","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3390\/cells12141904","article-title":"Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance","volume":"12","author":"Lovsund","year":"2023","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.cpet.2025.09.005_bib105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.120.246041","article-title":"Immune-checkpoint blockade Enhances225 Ac-PSMA617 efficacy in a mouse model of prostate cancer","volume":"62","author":"Czernin","year":"2021","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2025.09.005_bib106","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.tips.2020.09.005","article-title":"Beyond deterministic models in drug discovery and development","volume":"41","author":"Irurzun-Arana","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"13","key":"10.1016\/j.cpet.2025.09.005_bib107","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1007\/s00259-022-05891-w","article-title":"Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation","volume":"49","author":"Visvikis","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.cpet.2025.09.005_bib108","doi-asserted-by":"crossref","first-page":"778","DOI":"10.2967\/jnumed.124.268175","article-title":"Characterization of effective half-life for instant single-time-point dosimetry using machine learning","volume":"66","author":"Gomes","year":"2025","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2025.09.005_bib109","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1007\/s00259-022-05883-w","article-title":"Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy","volume":"49","author":"Xue","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2025.09.005_bib110","article-title":"A review of modern stochastic modeling: SDE\/SPDE numerics, data-driven identification, and generative methods with applications in biology and epidemiology","author":"Sabbar","year":"2025","journal-title":"arXiv"},{"issue":"2","key":"10.1016\/j.cpet.2025.09.005_bib111","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/mp.14622","article-title":"Important pharmacokinetic parameters for individualization of177 Lu-PSMA therapy: a global sensitivity analysis for a physiologically-based pharmacokinetic model","volume":"48","author":"Hardiansyah","year":"2021","journal-title":"Med Phys"},{"issue":"11","key":"10.1016\/j.cpet.2025.09.005_bib113","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metabol Dispos"},{"key":"10.1016\/j.cpet.2025.09.005_bib114","unstructured":"Zaid NRR, et al. PBPK modeling for radiopharmaceutical therapy: towards reliable digital twins via, verification, validation and uncertainty quantification (VVUQ). Pet Clin, 2026; Published online."},{"key":"10.1016\/j.cpet.2025.09.005_bib115","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-074819","article-title":"Evaluation of clinical prediction models (part 1): from development to external validation","volume":"384","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.cpet.2025.09.005_bib116","article-title":"Bayesian data assimilation to support informed decision-making in individualised chemotherapy","author":"Maier","year":"2019","journal-title":"arXiv"},{"issue":"15","key":"10.1016\/j.cpet.2025.09.005_bib117","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/bioinformatics\/btp358","article-title":"Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood","volume":"25","author":"Raue","year":"2009","journal-title":"Bioinformatics"},{"issue":"3\u20134","key":"10.1016\/j.cpet.2025.09.005_bib118","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0025-5564(70)90132-X","article-title":"On structural identifiability","volume":"7","author":"Bellman","year":"1970","journal-title":"Math Biosci"},{"key":"10.1016\/j.cpet.2025.09.005_bib119","unstructured":"Hardiansyah D, et al. An overview of PBPK and PopPK models: applications to radiopharmaceutical therapies for analysis and personalization. Pet Clin, 2026; Published online."},{"issue":"9","key":"10.1016\/j.cpet.2025.09.005_bib120","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3390\/pharmaceutics13091497","article-title":"Development of a compartmental pharmacokinetic model for molecular radiotherapy with 131I-CLR1404","volume":"13","author":"Neira","year":"2021","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.cpet.2025.09.005_bib112","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1118\/1.4747266","article-title":"Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy","volume":"39","author":"Kletting","year":"2012","journal-title":"Med Phys"},{"issue":"9","key":"10.1016\/j.cpet.2025.09.005_bib121","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"356","key":"10.1016\/j.cpet.2025.09.005_bib122","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/01621459.1976.10480949","article-title":"Science and statistics","volume":"71","author":"Box","year":"1976","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.cpet.2025.09.005_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2014.00021","article-title":"Why model?","volume":"5","author":"Wolkenhauer","year":"2014","journal-title":"Front Physiol"},{"issue":"24","key":"10.1016\/j.cpet.2025.09.005_bib124","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/aba21d","article-title":"A kinetic model of continuous radiation damage to populations of cells: comparison to the LQ model and application to molecular radiotherapy","volume":"65","author":"Neira","year":"2020","journal-title":"Phys Med Biol"},{"issue":"3","key":"10.1016\/j.cpet.2025.09.005_bib125","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ijrobp.2021.09.048","article-title":"Combined DNA damage repair interference and ion beam therapy: development, benchmark, and clinical implications of a mechanistic biological model","volume":"112","author":"Liew","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"supplement 1","key":"10.1016\/j.cpet.2025.09.005_bib126","article-title":"Parameter-refined PBPK modeling for enhanced dosimetry in 177Lu-PSMA radiopharmaceutical therapy using estimated and personalized parameters","volume":"66","author":"Tian","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib127","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.semnuclmed.2024.09.002","article-title":"Total-body PET\/CT: a role of artificial intelligence?","volume":"55","author":"Zhang","year":"2025","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.cpet.2025.09.005_bib128","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejmp.2017.07.024","article-title":"A review of GPU-Based medical image reconstruction","volume":"42","author":"Despr\u00e9s","year":"2017","journal-title":"Phys Med"},{"issue":"24","key":"10.1016\/j.cpet.2025.09.005_bib129","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.3390\/electronics10243118","article-title":"Hardware architectures for real-time medical imaging","volume":"10","author":"Alca\u00edn","year":"2021","journal-title":"Electronics"},{"issue":"18","key":"10.1016\/j.cpet.2025.09.005_bib130","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.3390\/cancers16183120","article-title":"Model-informed radiopharmaceutical therapy optimization: a study on the impact of PBPK model parameters on physical, biological, and statistical measures in 177Lu-PSMA therapy","volume":"16","author":"Abdollahi","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.cpet.2025.09.005_bib131","article-title":"Developing an agent-based mathematical model for simulating post-irradiation cellular response: a crucial component of a digital twin framework for personalized radiation treatment","author":"Liu","year":"2025","journal-title":"arXiv"},{"key":"10.1016\/j.cpet.2025.09.005_bib132","first-page":"44","article-title":"X-rays minibeam radiation therapy at a conventional irradiator: pilot evaluation in F98-glioma bearing rats and dose calculations in a human phantom","volume":"27","author":"Sotiropoulos","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2025.09.005_bib133","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3390\/cancers15041093","article-title":"Radiotherapy, PARP inhibition, and immune-checkpoint blockade: a triad to overcome the double-edged effects of each single player","volume":"15","author":"Rosado","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cpet.2025.09.005_bib134","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.122.264373","article-title":"Combined targeted radiopharmaceutical therapy and immune checkpoint blockade: from preclinical advances to the clinic","author":"Bellavia","year":"2022","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2025.09.005_bib135","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.cpet.2021.06.002","article-title":"Role of artificial intelligence in theranostics: toward routine personalized radiopharmaceutical therapies","volume":"16","author":"Brosch-Lenz","year":"2021","journal-title":"Pet Clin"},{"issue":"Supplement 1","key":"10.1016\/j.cpet.2025.09.005_bib136","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2024-198102","article-title":"Integration of [18f]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed DLBCL patients","volume":"144","author":"Dondolin","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cpet.2025.09.005_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pdig.0000801","article-title":"Implicit versus explicit Bayesian priors for epistemic uncertainty estimation in clinical decision support","volume":"4","author":"Blattmann","year":"2025","journal-title":"PLOS Digit Health"},{"issue":"6","key":"10.1016\/j.cpet.2025.09.005_bib138","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ac58dd","article-title":"Development of a GPU-Accelerated monte carlo dose calculation module for nuclear medicine, ARCHER-NM: demonstration for a PET\/CT imaging procedure","volume":"67","author":"Peng","year":"2022","journal-title":"Phys Med Biol"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib139","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40537-024-00929-2","article-title":"High-performance computing in healthcare: an automatic literature analysis perspective","volume":"11","author":"Li","year":"2024","journal-title":"J Big Data"},{"key":"10.1016\/j.cpet.2025.09.005_bib140","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-025-02252-9","article-title":"Governance of cross-border genomic data sharing through a human rights approach","author":"Yu","year":"2025","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.cpet.2025.09.005_bib141","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.cpet.2025.09.005_bib142","doi-asserted-by":"crossref","DOI":"10.1063\/5.0043509","article-title":"Actinium-225 production with an electron accelerator","volume":"129","author":"Diamond","year":"2021","journal-title":"J Appl Phys"},{"issue":"1","key":"10.1016\/j.cpet.2025.09.005_bib143","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12911-023-02115-5","article-title":"Interoperability of heterogeneous health information systems: a systematic literature review","volume":"23","author":"Torab-Miandoab","year":"2023","journal-title":"BMC Med Inform Decis Mak"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859825000914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859825000914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:46:15Z","timestamp":1763768775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859825000914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1556859825000914"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2025.09.005","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mathematical and Computational Nuclear Oncology","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}